Comment
Author: Admin | 2025-04-28
Based on clinical response RitonavirPossible decreased bupropion and hydroxybupropion exposure Increase in bupropion dosage may be necessary; do not exceed maximum recommended dosage TamoxifenPossible reduced efficacy of tamoxifen Increased dosage of tamoxifen may be necessary TheophyllinePossible lowering of seizure threshold; increased risk of seizures Use with extreme caution; initiate therapy with lower bupropion dosage and increase gradually VenlafaxinePossible decreased metabolism of venlafaxine Decrease dosage of venlafaxine if necessary WarfarinPossible altered PT/INR; infrequently associated with hemorrhagic or thrombotic complications Bupropion Hydrobromide PharmacokineticsAbsorptionBioavailabilityWell-absorbed from the GI tract following oral administration. Peak plasma concentrations usually occur within 2, 3, or 5 hours after oral administration of conventional or extended-release bupropion hydrochloride tablets of Wellbutrin SR or Wellbutrin XL, respectively. Peak plasma concentrations occur within approximately 5 or 12 hours under fasted or fed conditions, respectively, after oral administration of extended-release, 450-mg bupropion hydrochloride tablets (Forfivo XL). Peak plasma concentrations occur within approximately 5 hours after oral administration of extended-release bupropion hydrobromide tablets (Aplenzin).Steady-state plasma concentrations of bupropion achieved within 8 days.At steady state, conventional and extended-release tablets (Wellbutrin SR, Wellbutrin XL) are essentially bioequivalent. Bupropion hydrochloride extended-release, 450-mg tablets (Forfivo XL) and bupropion hydrobromide extended-release tablets (Aplenzin) are bioequivalent to bupropion hydrochloride extended-release tablets (e.g., Wellbutrin XL), Bupropion hydrobromide doses of 174, 348, or 522 mg are equivalent to bupropion hydrochloride doses of 150, 300, or 450 mg, respectively.FoodFood does not appear to substantially affect the peak plasma concentration or extent of absorption achieved with extended-release tablets. DistributionExtentBupropion and its metabolites are distributed into milk. Plasma Protein Binding84% bound to human albumin. EliminationMetabolismExtensively metabolized in the liver to 3 active metabolites: hydroxybupropion (principally by CYP2B6), threohydrobupropion, and erythrohydrobupropion. CYP isoenzymes not involved in the formation of threohydrobupropion and erythrohydrobupropion metabolites. Elimination RouteExcreted in urine (87%) and feces (10%), principally as metabolites. Half-lifeThe half-life
Add Comment